相关实验视频

Updated: May 5, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

90Y-FAPI-46在肉瘤和其他固体瘤中的放射性药物疗法:更新的队列分析

Helena Lanzafame^1,2, Ilektra A Mavroeidi^2,3, Kim M Pabst^4,2

¹Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany; helena.lanzafame@uk-essen.de.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

|February 19, 2026

概括

放射性药物治疗的Y-FAP抑制剂 (FAPI) -46在患有晚期癌症的患者中显示出有利的安全概况,特别是肉瘤. 在近一半的患者中观察到疾病稳定,支持其在肉瘤治疗中的作用.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射性药物疗法是一种放射性药物疗法.

背景情况:

纤维细胞激活蛋白 (FAP) 是许多癌症的关键标,特别是肉瘤.
90Y-FAP抑制剂 (FAPI) -46为表达FAP的瘤提供了一种治疗方法.

研究的目的:

评估Y-FAPI-46治疗在晚期肉瘤和其他固体瘤患者的长期安全性和疗效.
评估Y-FAPI-46治疗后的瘤反应和生存结果.

主要方法:

对30名患有进展性或转移性癌症和高FAP表达 (SUV_max,≥10) 的患者进行了回顾性分析.
患者在已批准的治疗方法耗尽后接受了Y-FAPI-46治疗.
瘤反应通过RECIST和PERCIST进行评估;不良事件通过CTCAE v5.0.0进行分级.

主要成果:

观察到48%的疾病控制 (RECIST) 和60%的代谢反应 (PERCIST).
疾病控制与改善的整体存活率相关 (14.6 vs 1.9 个月).
证实了有利的安全性概况,具有可控的血液毒性 (任何等级在67%,等级≥3在27%).

结论:

90 治疗Y-FAPI-46表明了有利的长期安全性.
疾病稳定,主要是在瘤中,支持FAP导向的放射性药物治疗.
Y-FAPI-46 是转移性肉瘤患者的一个有前途的治疗选择.

关键词:

90Y-FAPI-46 的使用情况.放射性药物疗法是一种放射性药物疗法.这种类型的瘤是sarcomas.他们是天文学家.

更多相关视频

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...